News Detail
New Delhi, 29 June 2024: Popular peptide drugs for diabetes and obesity — Glucagon-like peptide receptor agonist (GLP-1RA) — will be manufactured in India under the production linked incentive (PLI) scheme from 2026 when the patents expire, a ......
View Details
View Details
Source : Business Standard
diabetes medicine
sun pharmaceutical industries ltd
cipla ltd
India Ozempic
Obesity
Obesity medicine
Obesity drugs
Obesity medicines
diabetes
diabetes drugs
Related News
- Govt launches portal to tackle drug abuse in children (02-07-2024)
- Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge (02-07-2024)
- Man who illegally imported unlicensed medicines from India, sentenced at Southwark Crown Court (02-07-2024)
- Punjab HM bats for bringing parity in prices of same salt medicines (02-07-2024)
- After Gilead and J&J lawsuits, Safe Chain owners charged with wire fraud, conspiracy (02-07-2024)
- Indian national charged with selling counterfeit drugs (02-07-2024)
- Punjab police bust illegal pharma drug Unit, 4 arrested (02-07-2024)
- Pharma sector sees Rs. 29,268 crore increase under PLI scheme by May 2024 (01-07-2024)
- Mumbai: Drug lord reveals a web of ops (01-07-2024)
- UP Man Arrested in Major Fake Medicine Racket (01-07-2024)